Dicerna To Present Advances In Conjugate Delivery Technology At Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 4th Annual Rare Disease Roundtable. The presentation will take place on Wednesday, September 30, 2015 at 10:40 a.m. ET at Le Parker Meridien Hotel in New York City.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC